ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses (UKHVCSpoke003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01922284
Recruitment Status : Completed
First Posted : August 14, 2013
Last Update Posted : September 27, 2016
Sponsor:
Collaborators:
Medical Research Council
Wellcome Trust
Information provided by (Responsible Party):
Imperial College London

Brief Summary:

UKHVC Spoke 003 is a randomised Phase I, two centre study which will explore the impact of shortening a vaccination regimen using deoxyribonucleic acid (DNA) (CN54ENV and ZM96GPN), Modified Vaccinia Ankara - C (MVA-C) and CN54rgp140 adjuvanted with glucopyranosyl lipid A adjuvant - aqueous form (GLA-AF). The study population will be 40 healthy male and female volunteers 18 to 45 years old who are at low risk of HIV infection are to be recruited.

Study participants will be immunised with trial immunogens:

  • 8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
  • 1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade-C 97CN54
  • 100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
  • 5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant

All immunisations will be administered by the intramuscular route (IM). CN54gp140 and GLA will be mixed together before administration, and immunogens will be delivered in combination regimens


Condition or disease Intervention/treatment Phase
HIV Biological: DNA Biological: MVA-C Biological: CN54rgp140 Biological: GLA-AF Phase 1

Detailed Description:

This is a phase I study exploring the safety and potency of five HIV vaccines in healthy volunteers. The main aim is to see whether three of the five vaccines can be given together rather than one after the other, in five rather than seven sets of vaccinations and a course shortened by eight weeks. All volunteers will receive three injections of the first two vaccines (DNA plasmids) and half will be randomly assigned to receive two injections each of the second (MVA-C) and subsequent vaccines (CN54rgp140 mixed with GLA-AF) during the same visit or two injections of the MVA-C followed by two of CN54rgp140 mixed with GLA-AF.

The investigators are interested in ensuring that the vaccines are safe and also that the immune responses in the two groups of volunteers are similar. The three vaccines have all been shown to stimulate the immune response to specific parts of the HIV virus and none are infectious. The first vaccine consists of two DNA plasmids. When injected into muscle cells small parts of the HIV virus which are encoded by the DNA are produced and these are then recognised by the immune system. The second vaccine MVAC, is derived from vaccinia virus which has been modified so that it cannot divide. The virus (Modified Vaccinia Ankara (MVA)) actually expresses the same portions of HIV as the DNA and results in amplification of the responses seen. The third vaccine is a synthetically produced component of the HIV viral outer coat and it will be administered with an additive which has been shown to greatly enhance particular types of immune response which have recently been shown to play a role in protection against infection


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase I Clinical Trial Investigating Immunisation Strategies Using DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses
Study Start Date : June 2013
Actual Primary Completion Date : January 2014
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Group 1 - Combination arm

All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 1 will receive 5 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8 16 and 20.

At weeks 16 and 20, individuals in group 1 will be given MVAC in a volume of 0.5mls into the upper left arm and also 100ug CN54rgp140 mixed with 5ug GLA-AF in a total volume of 0.4mls into the muscle of the upper right arm.

Biological: DNA
8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54

Biological: MVA-C
1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54

Biological: CN54rgp140
100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54

Biological: GLA-AF
5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant

Active Comparator: Group 2 - Non-combination arm

All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 2 will receive 7 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8, 16, 20, 24 and 28.

At weeks 16 & 20 group 2 will receive only 0.5mls of MVAC into the muscle of the upper left arm. At weeks 24 and 28 they will receive injections of 100ug CN54rgp140 mixed with 5ugGLAAF in a total volume of 0.4mls into the muscle of the upper right arm.

Biological: DNA
8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54

Biological: MVA-C
1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54

Biological: CN54rgp140
100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54

Biological: GLA-AF
5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant




Primary Outcome Measures :
  1. Magnitude of antibody response [ Time Frame: Four weeks after final immunisation ]
    Magnitude (reciprocal mean endpoint titre and concentration) of systemic Immunoglobulin G (IgG) binding antibody responses to CN54rgp140 measured four weeks after the final immunisation.

  2. Adverse Events [ Time Frame: Every four weeks up to 32 weeks ]
    Grade 3 or above local solicited adverse event Grade 3 or above systemic clinical and laboratory solicited adverse event Any grade of adverse event that results in a clinical decision to discontinue further immunisations


Secondary Outcome Measures :
  1. Magnitude of neutralising antibody (Nab) responses [ Time Frame: Four weeks after the final immunisation ]
    Confirmation of specific investigations will be provided at a later date.

  2. Magnitude of T-cell and B-cell responses [ Time Frame: Four weeks after the final immunisation ]
    Confirmation of specific investigations will be provided at a later date.

  3. Magnitude of mucosal IgG and IgA antibody responses [ Time Frame: Four weeks after the final immunisation ]
    Confirmation of specific investigations will be provided at a later date.

  4. Magnitude of antibody-dependent cell-mediated cytotoxicity or Antibody-dependent cell-mediated viral inhibition [ Time Frame: From first immunisation ]
    Confirmation of specific investigations will be provided at a later date.

  5. Magnitude of systemic Immunoglobulin A (IgA) binding antibody responses [ Time Frame: Four weeks after the final immunisation ]
    Confirmation of specific investigations will be provided at a later date.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Man or woman aged between 18 and 45 years on the day of screening
  2. Available for follow-up for the duration of the study (up to ~10 months from enrolment)
  3. At low risk of HIV and willing to remain so for the duration of the study defined as:

    • no history of injecting drug use in the previous ten years
    • no gonorrhoea or syphilis in the last six months
    • no high risk partner (e.g. injecting drug use, HIV positive partner) either currently or within the past six months
    • no unprotected anal intercourse in the last six months, outside a relationship with a regular partner known to be HIV negative
    • no unprotected vaginal intercourse in the last six months outside a relationship with a regular known/presumed HIV negative partner
  4. Willing to undergo an HIV test
  5. Willing to undergo a genital infection screen if indicated by sexual history
  6. If heterosexually active female, using an effective method of contraception with partner other than an IUCD/IUS (combined oral contraceptive pill; injectable or implanted contraceptive; consistent record with condoms if using these; physiological or anatomical sterility in self or partner) from 14 days prior to the first vaccination until 4 months after the last, and willing to undergo urine pregnancy tests prior to each vaccination
  7. If heterosexually active male, using an effective method of contraception with their partner from the first day of vaccination until 4 months after the last vaccination
  8. Agree to abstain from donating blood for three months after the end of their participation in the trial, or longer if necessary
  9. Registered with a general practitioner (GP) for at least the past three months
  10. Satisfactory response received from GP before randomisation
  11. Willing and able to give written informed consent

Exclusion Criteria:

  1. Pregnant or lactating
  2. Presence of an IUCD (intrauterine contraceptive device)/IUS (intrauterine system)
  3. Clinically relevant abnormality on history or examination including

    • history of grand-mal epilepsy, seizure disorder or any history of prior seizure
    • severe eczema
    • liver disease with inadequate hepatic function
    • any skin condition which may interfere with the trial assessment on the injection site
    • haematological, metabolic, gastrointestinal or cardio-pulmonary disorders
    • uncontrolled infection; toxic shock syndrome; autoimmune disease, immunodeficiency or use of immunosuppressives in preceding 3 months
  4. Known hypersensitivity to any component of the vaccine formulations used in this trial, or have severe or multiple allergies to drugs or pharmaceutical agents
  5. History of severe local or general reaction to vaccination defined as

    1. local: extensive, indurated redness and swelling involving the major circumference of the arm, not resolving within 72 hours
    2. general: fever >= 39.5°C within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours
  6. Receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of enrolment
  7. Receipt of an experimental vaccine containing HIV antigens at any time in the past
  8. Receipt of blood products or immunoglobin within 4 months of screening
  9. Participation in another trial of a medicinal product, completed less than 30 days prior to enrolment
  10. HIV 1 or 2 positive or indeterminate on screening
  11. Positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating active syphilis requiring treatment
  12. Grade 1 or above routine laboratory parameters. Hyperbilirubinaemia to be considered an exclusion criterion only when confirmed to be conjugated bilirubinaemia
  13. Unable to read and speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent.
  14. Unlikely to comply with protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01922284


Locations
United Kingdom
Surrey Clinical Research Centre, University of Surrey
Guildford, Surrey, United Kingdom, GU2 7XP
Imperial College London
Greater London, United Kingdom, W2 1PG
Sponsors and Collaborators
Imperial College London
Medical Research Council
Wellcome Trust
Investigators
Principal Investigator: Sheena McCormack, MSc, FRCP Senior Clinical Scientist

Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT01922284     History of Changes
Other Study ID Numbers: CRO2059
2012-003277-26 ( EudraCT Number )
First Posted: August 14, 2013    Key Record Dates
Last Update Posted: September 27, 2016
Last Verified: August 2013

Keywords provided by Imperial College London:
HIV
Vaccine
Immunisation
DNA
Adverse events
MVA-C
GLA-AF
Antibody

Additional relevant MeSH terms:
Vaccines
Antibodies
Immunoglobulins
Immunologic Factors
Physiological Effects of Drugs